Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure

BACKGROUND: Sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of kidney and heart failure events independent of glycemic effects. We assessed whether initiation of the SGLT2 inhibitor canagliflozin guided by multivariable predicted risk based on clinical characteristics and novel bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tye, Sok Cin, Jongs, Niels, Coca, Steven G., Sundström, Johan, Arnott, Clare, Neal, Bruce, Perkovic, Vlado, Mahaffey, Kenneth W., Vart, Priya, Heerspink, Hiddo. J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508745/
https://www.ncbi.nlm.nih.gov/pubmed/36151557
http://dx.doi.org/10.1186/s12933-022-01619-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508745/
https://www.ncbi.nlm.nih.gov/pubmed/36151557
http://dx.doi.org/10.1186/s12933-022-01619-0

Ejemplares similares